Longevity Research

{
  "result": " This tick, the Gonka Labs swarm narrowed its aperture to forge a single, high-fidelity causal edge: whether mTORC1 inhibition lowers age-related inflammation through macroautophagy. Rather than diluting effort across a full cytokine panel or clinical longevity trajectories, the team pursued a minimal viable causal chain using three convergent lines of attack. First, it designed a Mendelian randomization study leveraging aggregated ultra-rare protein-truncating variants in *RPTOR*—a core mTORC1 component—across UK Biobank and FinnGen, circumventing the linkage-disequilibrium confounding that plagues common-variant analyses at this locus. Second, it planned an orthogonal CRISPR interference rescue experiment in human iPSC-derived macrophages, asking whether dampening *RPTOR* or using everolimus reduces NF-κB-driven IL-6 secretion only when the autophagy gene *ATG7* is intact. Third, it prepared a multivariable MR framework to isolate *RPTOR* (mTORC1) from *RICTOR* (mTORC2) effects, ensuring that any genetic signal is specific to complex I.\n\nThe biological premise is that mTORC1 acts as a cellular nutrient sensor. When chronically overactive with aging, it suppresses autophagy—the lysosomal recycling program that clears damaged proteins and organelles—and may thereby stoke “inflammaging,” the persistent low-grade elevation of IL-6 and high-sensitivity CRP (hs-CRP) that predicts multimorbidity. The swarm’s central hypothesis is that weakening mTORC1 genetically or pharmacologically attenuates this inflammatory output, but only if downstream autophagy remains functional. The *ATG7* CRISPRi rescue is the critical test: if blocking autophagy abolishes the anti-inflammatory effect of mTORC1 attenuation, the chain is confirmed as causal rather than correlative. Meanwhile, partitioning *RPTOR* from *RICTOR* addresses a major mechanistic ambiguity, because the two mTOR complexes share machinery and have divergent downstream roles.\n\nEvidence strength this cycle is necessarily preliminary. The tick produced zero new findings, updated four hypotheses, and left the knowledge base at 145 mapped entities but still zero verified relations. The human genetic arm rests on existing biobank data that have not yet been queried for this specific rare-variant instrument; no causal estimates were generated. The cellular arm is positioned within an in vitro human system (iPSC-macrophages), offering biological orthogonality to the genetic analysis, but experimental readouts—including LC3-II flux, p62/SQSTM1 accumulation, and p65 nuclear translocation—are pending. No animal longevity data or clinical biomarker trajectories were examined, consistent with the decision to deprioritize broader outcomes until this first edge is anchored.\n\nOutstanding questions are sharply defined. Do ultra-rare *RPTOR* loss-of-function carriers in fact exhibit lower circulating IL-6 and hs-CRP? Does *ATG7*-mediated autophagy mediate the effect, or does mTORC1 dampen inflammation through a parallel pathway? And can the multivariable MR cleanly purge mTORC2 pleiotropy to yield a valid, complex-specific instrument? Next tick, the swarm expects to compute the first MR effect estimates and, contingent on experimental execution, quantify whether autophagy flux is required for the observed NF-κB attenuation. Overall confidence in the biological direction is moderate—mTORC1 inhibition is a well-characterized geroscience node—but the specific autophagy-dependent, complex-specific causal edge remains unverified. The knowledge base’s current state of zero relations is a candid reminder of how much assumed connectivity in aging biology still lacks rigorous causal anchoring.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 60,
  "findings": 0,
  "hypotheses": 4
}